Patients with CRSwNP see smaller nasal polyps, less congestion
Dec 18, 2024 · Patients with severe chronic rhinosinusitis with nasal polyps experienced significant improvements in their symptoms with tezepelumab-ekko compared with placebo, according to a press release from...
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal …
Oct 14, 2024 · On Monday, GSK plc (NYSE: GSK) released headline results from the phase 3 trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with chronic...
GSK Announces Positive Phase III Results from ANCHOR Trials for ...
14 October 2024 -- GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials ANCHOR-1 and ANCHOR-2, which assessed the efficacy and safety of depemokimab versus placebo in adults with CRSwNP.
GSK’s Nucala Gains Approval in China for CRSwNP - Yahoo Finance
6 days ago · GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 ...
Tezspire Meets Co-primary Endpoints in Phase 3 WAYPOINT Trial
Nov 11, 2024 · A Phase III trial, WAYPOINT, has yielded positive results for AstraZeneca and Amgen’s TEZSPIRE (tezepelumab) in treating chronic rhinosinusitis with nasal polyps (CRSwNP). The randomized, double-blind trial demonstrated that TEZSPIRE significantly reduced nasal polyp size and nasal congestion compared to a placebo in adults with severe CRSwNP.
GSK Says Depemokimab For Chronic Rhinosinusitis Reduces
Oct 14, 2024 · GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise in reducing nasal polyp growth and obstruction. Full results to be...
Dupixent receives FDA approval as first CRSwNP treatment
Sep 16, 2024 · The US Food and Drug Administration (FDA) has expanded the approval of Dupixent (dupilumab) to include adolescents aged 12 to 17 years with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
Dupilumab in CRSwNP Gave Patients Significantly More Symptom …
Nov 4, 2024 · Dupilumab significantly improves the day-to-day symptom burden in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), according to study findings published in Annals of Allergy, Asthma & Immunology.
Dupilumab for Chronic Rhinosinusitis With Nasal Polyps Is Effective
Dec 2, 2024 · Dupilumab was effective for patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) at 52 weeks, researchers reported in the Journal of Allergy and Clinical Immunology. Researchers conducted an observational, retrospective study evaluating the effectiveness of dupilumab in a large-scale CRSwNP cohort from 6 tertiary
FDA Approves Dupilumab for Adolescents with Chronic …
Sep 13, 2024 · The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as an add-on maintenance therapy for individuals aged 12 - 17 years with chronic rhinosinusitis with nasal polyposis (CRSwNP). 1. The decision also expands the drug’s age range following the June 2019 approval for CRSwNP among those aged 18 years and older.